CO6251377A2 - Compuestos de imidazo - Google Patents

Compuestos de imidazo

Info

Publication number
CO6251377A2
CO6251377A2 CO09120874A CO09120874A CO6251377A2 CO 6251377 A2 CO6251377 A2 CO 6251377A2 CO 09120874 A CO09120874 A CO 09120874A CO 09120874 A CO09120874 A CO 09120874A CO 6251377 A2 CO6251377 A2 CO 6251377A2
Authority
CO
Colombia
Prior art keywords
compounds
class
inhibitors
imidazo compounds
receptor
Prior art date
Application number
CO09120874A
Other languages
English (en)
Inventor
Shelley Allen
Julie Marie Greschuk
Nicholas C Kallan
Fredrik Pehr Marmsater
Mark Munson
James Rizzi
John Robinson
Stephen Schlachter
George Topalov
Qian Zhao
Joseph Lyssikatos
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CO6251377A2 publication Critical patent/CO6251377A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Se describen los compuestos de la Fórmula I: en los cuales A, B, R1, R1a, R2, R3, R4, R5 R6, R7 y R8 tienen los significados dados en la especificación, que son inhibidores de la tirosina receptora, útiles en el tratamiento de enfermedades mediadas por tirosina-cinasas receptoras de la clase 3 y de la clase 5. Los compuestos particulares de esta invención han sido también encontrados como inhibidores de Pim-1.
CO09120874A 2007-04-03 2009-10-27 Compuestos de imidazo CO6251377A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90985707P 2007-04-03 2007-04-03

Publications (1)

Publication Number Publication Date
CO6251377A2 true CO6251377A2 (es) 2011-02-21

Family

ID=39539641

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09120874A CO6251377A2 (es) 2007-04-03 2009-10-27 Compuestos de imidazo

Country Status (26)

Country Link
US (1) US8138181B2 (es)
EP (1) EP2137184B1 (es)
JP (1) JP5374492B2 (es)
KR (1) KR101538179B1 (es)
CN (2) CN103214482B (es)
AU (1) AU2008237507B2 (es)
BR (1) BRPI0809998B8 (es)
CA (1) CA2682981C (es)
CO (1) CO6251377A2 (es)
CY (1) CY1114277T1 (es)
DK (1) DK2137184T3 (es)
ES (1) ES2420113T3 (es)
HK (1) HK1140200A1 (es)
HR (1) HRP20130660T1 (es)
IL (1) IL201300A0 (es)
MX (1) MX2009010728A (es)
MY (1) MY157724A (es)
NZ (1) NZ580327A (es)
PL (1) PL2137184T3 (es)
PT (1) PT2137184E (es)
RS (1) RS52862B (es)
RU (1) RU2467008C2 (es)
TW (1) TWI429434B (es)
UA (1) UA101611C2 (es)
WO (1) WO2008124323A1 (es)
ZA (1) ZA200907674B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
EP3495369B1 (en) 2007-06-13 2021-10-27 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
WO2010039825A2 (en) * 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596961B (zh) 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
RU2562977C2 (ru) * 2009-12-21 2015-09-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО N-(1Н-ИНДАЗОЛ-4-ИЛ)ИМИДАЗОЛ[1,2-a]ПИРИДИН-3-КАРБОКСАМИДА КАК ИНГИБИТОРЫ cFMS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MX2012012145A (es) * 2010-04-28 2012-11-21 Daiichi Sankyo Co Ltd Compuestos [5, 6] heterociclico.
MX365251B (es) 2010-05-20 2019-05-28 Array Biopharma Inc Compuestos macrocíclicos como inhibidores de trk cinasa.
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CA3027814A1 (en) 2010-12-13 2012-06-21 Array Biopharma Inc. Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as intermediates for type iii receptor tyrosine kinase inhibitors
WO2012154274A1 (en) * 2011-02-25 2012-11-15 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN103214481B (zh) * 2012-01-21 2016-08-03 中国科学院上海药物研究所 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
US9738636B2 (en) 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
EA030705B1 (ru) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
US9394254B2 (en) * 2013-05-08 2016-07-19 The University of Denver and Regis University Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
ES2792549T3 (es) 2013-08-07 2020-11-11 Incyte Corp Formas de dosificación de liberación sostenida para un inhibidor de JAK1
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
CN113354649A (zh) 2014-11-16 2021-09-07 阵列生物制药公司 一种新的晶型
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
EP3512834A4 (en) * 2016-09-14 2020-05-06 Vanderbilt University INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PL3746429T3 (pl) 2018-01-30 2022-06-20 Incyte Corporation Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CN110833554B (zh) * 2018-08-15 2022-03-08 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗自身免疫性甲状腺疾病的用途
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CA2401368A1 (en) * 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
KR100732206B1 (ko) * 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
ES2310202T3 (es) 2001-04-26 2009-01-01 EISAI R&D MANAGEMENT CO., LTD. Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo.
CA2483084A1 (en) 2002-05-02 2003-11-13 Merck & Co., Inc. Tyrosine kinase inhibitors
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
DE10246890A1 (de) * 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7205316B2 (en) * 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
CA2582479C (en) 2004-10-07 2011-07-12 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
EP2606890A1 (en) 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CN101679422A (zh) * 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
WO2010039825A2 (en) * 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS

Also Published As

Publication number Publication date
CN103214482B (zh) 2016-06-29
WO2008124323A1 (en) 2008-10-16
HRP20130660T1 (en) 2013-08-31
RU2467008C2 (ru) 2012-11-20
MY157724A (en) 2016-07-15
RS52862B (en) 2013-12-31
EP2137184B1 (en) 2013-05-08
JP5374492B2 (ja) 2013-12-25
ZA200907674B (en) 2013-04-24
EP2137184A1 (en) 2009-12-30
UA101611C2 (ru) 2013-04-25
CA2682981C (en) 2015-11-17
RU2009140407A (ru) 2011-05-10
DK2137184T3 (da) 2013-07-22
PT2137184E (pt) 2013-08-01
BRPI0809998B8 (pt) 2021-05-25
MX2009010728A (es) 2009-10-26
TW200900063A (en) 2009-01-01
IL201300A0 (en) 2010-05-31
BRPI0809998A2 (pt) 2014-10-14
AU2008237507B2 (en) 2014-03-20
BRPI0809998B1 (pt) 2019-12-31
US20100029633A1 (en) 2010-02-04
CA2682981A1 (en) 2008-10-16
TWI429434B (zh) 2014-03-11
NZ580327A (en) 2012-02-24
CN103214482A (zh) 2013-07-24
KR101538179B1 (ko) 2015-07-20
KR20090126320A (ko) 2009-12-08
HK1140200A1 (en) 2010-10-08
CY1114277T1 (el) 2016-08-31
PL2137184T3 (pl) 2013-09-30
US8138181B2 (en) 2012-03-20
AU2008237507A1 (en) 2008-10-16
JP2010523576A (ja) 2010-07-15
CN101679423A (zh) 2010-03-24
ES2420113T3 (es) 2013-08-22

Similar Documents

Publication Publication Date Title
CO6251377A2 (es) Compuestos de imidazo
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CR8744A (es) Compuestos terapeuticos
PA8631601A1 (es) Nuevos compuestos
CO6440551A2 (es) Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
PA8809001A1 (es) Compuestos organicos
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR8888A (es) Indazoles utiles en el tratamiento de enfermedades cardiovasculares
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY30291A1 (es) Piridin(3,4-b)pirazinonas
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
PA8667201A1 (es) Nuevos compuestos farmaceuticos
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
HN2008000817A (es) Derivados de oxadiazol
PA8803201A1 (es) Derivados acidos de cicloalquilamino
PA8616801A1 (es) Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos

Legal Events

Date Code Title Description
FG Application granted